Roxadustat approval – Astellas Pharma and FibroGen have secured approval for EVRENZO (roxadustat) in Japan for the treatment of anemia associated with chronic kidney disease (CKD) in adults, who are not on dialysis. The approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) is the second in the country for roxadustat through the […]
Continue reading …Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission (EC) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. The approval of the once-daily, oral, JAK1 inhibitor is rheumatoid arthritis patients who showed inadequate response […]
Continue reading …Santen acquisition of Eyevance : Santen Pharmaceutical, a Japanese pharma company specialized in ophthalmology, has acquired US ophthalmic company Eyevance Pharmaceuticals for $225 million in cash. The acquisition was undertaken by the company’s fully-owned subsidiary Santen Holdings U.S. Established only a couple of years ago, Eyevance Pharmaceuticals develops and commercializes topical ophthalmic products that target the […]
Continue reading …SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. Cenobamate was approved by the US Food and Drug Administration as an anti-seizure medication (ASM) under the brand name XCOPRI for the treatment of partial-onset seizures in adults. (Read here […]
Continue reading …Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint of progression-free survival (PFS). The late-stage trial assessed the combination of NINLARO (ixazomib) with lenalidomide and dexamethasone in comparison to lenalidomide and dexamethasone plus placebo […]
Continue reading …Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm for about $562 million. The portfolio to be offloaded to Cheplapharm is made up of non-core prescription pharma products in a range of therapeutic segments. This includes cardiovascular/metabolic and anti-inflammatory […]
Continue reading …Japanese pharma giant Takeda Pharmaceutical has agreed to sell its consumer healthcare business to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group and its affiliates (collectively Blackstone) for JPY 242 billion ($2.3 billion). The business being divested- Takeda Consumer Healthcare Company (TCHC) is focused on the consumer health care market […]
Continue reading …US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former’s COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is said to be a stable, prefusion protein produced by using the recombinant protein nanoparticle technology of Novavax. The coronavirus vaccine candidate also contains the company’s Matrix‑M adjuvant. Takeda […]
Continue reading …AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter’s DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), which is being developed for the treatment of multiple tumor types. Daiichi Sankyo is developing the antibody drug conjugate for multiple tumors […]
Continue reading …